Recurrent pregnancy loss (RPL) affects nearly 5% of the women of reproductive age. Its heterogeneous 20 and multifactorial nature complicate both diagnosis and treatment, as well as identification of the genetic 21 contribution to RPL. Evidence about the aetiology of RPL is controversial; however, several biological 22 mechanisms have been proposed. Given the current knowledge about the genetic susceptibility to 23 idiopathic RPL, we aimed to evaluate the predictive ability of a combined variant panel to the risk of 24 RPL in the Ukrainian sample of 114 cases and 106 healthy controls. We genotyped variants within the 25 12 genetic loci reflecting the main biological pathways involved in pregnancy maintenance: blood 26 coagulation (F2, F5, F7, GP1A) , hormonal regulation (ESR1, ADRB2), endometrium and placental 27 function (ENOS, ACE), folate metabolism (MTHFR) and inflammatory response (IL6, IL8, IL10). We 28 showed that a genetic risk score (GRS) calculated from the 12 variants was associated with an increased 29 risk of RPL (odds ratio 1.56, 95% CI: 1.21,2.04, P=8.7x10 -4 ). The receiver operator characteristic 30 (ROC) analysis resulted in the area under the curve (AUC) of 0.64 (95% CI: 0.57, 0.72), indicating an 31 improved ability of the GRS to classify women with and without RPL. In summary, implementation of 32 the GRS approach can help defining women at higher risk to complex multifactorial conditions such as 33 RPL. Future well-powered genome-wide association studies will help in the dissection of biological 34 pathways not hypothesised previously for RPL and further improve the prediction and identification of 35 those at risk for RPL. 36 37 38
Introduction 39
The loss of two or more sequential pregnancies in the first trimester of gestation is defined as recurrent 40 pregnancy loss (RPL)(1). Nearly one in twenty women of reproductive age is affected by this 41 condition(2). Heterogeneity and multifactorial nature of RPL complicate both diagnosis and treatment 42 of RPL, thus causing severe distress for affected couples and their clinicians (3, 4) . Despite a large 43 number of clinical and genetic studies aiming to identify probable causes and suitable treatments of 44 RPL, most of the findings remain controversial and demand replication (3, 5) . 45
46
The vast majority of early pregnancy losses (50%-60%) are the consequence of chromosomal 47 abnormalities, which can be of parental origin, or arise de novo in the embryo from parents with normal 48 chromosomes(6,7). Nonetheless, endocrine, immunological, anatomical and other hypotheses are 49
proposed to play a leading role in RPL aetiology, with most of the remaining RPL cases being 50 idiopathic (5, 8) . In patients with idiopathic RPL, a multifactorial nature of the condition is usually 51 suggested, with genetic component viewed as an important risk factor (5, 9, 10) . Large-scale genome-52 wide association studies (GWAS) in appropriately defined individuals should enable better dissection 53 of pregnancy maintenance/loss mechanisms, as well as provide evaluation of miscarriage risks in 54 couples with reproductive complications. However, the genetic susceptibility to RPL in female health 55
has not been addressed. The identification of RPL cases is laborious and expensive, hindering the setup 56 of a well-powered GWAS for this outcome. Many studies, including the UK Biobank consisting of 57 500,000 individuals, have collected data on self-reported miscarriages and the number of spontaneous 58 miscarriages. GWAS on the UK Biobank data(11) on such surrogate phenotypes for RPL have not 59 resulted in any common variants associated with RPL at genome-wide significance, plausibly reflecting 60 an inaccurate re-call and complex genetic susceptibility to RPL. 61
62 While more precise data on idiopathic RPL are being collected allowing well-powered GWAS in the 63 future, our best approach is to look at the potential biological mechanisms proposed for RPL 64 pathogenesis and use such information to infer the potentially relevant genes in RPL susceptibility. The 65 suggested mechanisms include alterations in blood coagulation, hormonal regulation, endometrium and 66 placental function, folate metabolism and inflammatory response. 67 68 Blood coagulation. Haemostasis-related genes, such as the coagulation factor II and V genes (F2 and 69 F5, respectively), have been linked to venous thromboembolism and thrombosis in recent GWAS(12-70 15). They contribute to hereditary thrombophilia, and it has been suggested that they could act 71 throughout pregnancy, causing miscarriages(16). Indeed, a study on F2 and F5 genes has shown 72 associations with variation in these genes and RPL(17). Associations between polymorphisms in the 73 coagulation factor VII (F7) gene and recurrent miscarriages were also reported in a study from 74
Poland (18) . Another strong candidate within the blood coagulation pathway to RPL is the glycoprotein 75 Ib (platelet), alpha (GP1A) gene which is an important player in the platelet adhesion to collagen (19) . 76 77 Hormonal regulation. The relevance of hormonal regulation in the susceptibility of RPL comes from 78 the knowledge that estrogens modulate multiple reproductive functions, including progesterone 79 production and uteroplacental blood flow(20). Estrogen receptors (ERs), which in human consist of ERα 80 and ERβ, encoded by ESR1 and ESR2 genes, respectively, are mediators of estrogen signalling and 81 function (21, 22) . A study of ESR1 locus variants and RPL did not yield support for the association(23); 82 however, recent GWAS have linked variation within ESR1 to susceptibility to endometriosis(24) and to 83 maternal age at first birth(25). Stress-induced adrenergic receptor (ADRB2) activation may in turn 84 directly affect embryo-maternal interactions during implantation, resulting in pregnancy complications 85 and miscarriage (26) . No studies have directly assessed the association with variation in this gene and 86 RPL; however, controversial reports for the effects of ADRB2 variants have been reported on preterm 87 delivery (27,28) and its potential role was suggested as being a drug target for prevention of preterm 88 delivery (29). Variability within these genes may result in gestational complications, including pregnancy loss, pre-94 eclampsia, intrauterine foetal death and growth restriction (30). More specifically, variability in ACE is 95 associated with RPL (31). The ACE gene, which generates angiotensin II from angiotensin I as a potent 96 vasopressor (32,33), is a key component of the rennin-angiotensin system (RAS) that affects 97 homeostasis (34). There is evidence that the presence of the D allele or D/D genotype is correlated with 98 elevated plasma and tissue-specific ACE activity (35, 36) . In turn, eNOS is the main enzyme required 99 for vascular NO production, by converting L-arginin to L-citrulline. eNOS is expressed in the terminal 100 chorionic villous vessels and in the cyto-and syncytio-trophoblast layers during the first trimester (37) . 101 102 Folate metabolism. Variation within the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene is 103 associated with higher homocysteine (38,39) and serum folate concentrations (40) . Mild elevations in 104 the total plasma homocysteine (tHcy) concentration, a risk factor for placental abruption, and infarction 105 and preeclampsia (41) , are also associated with an increased risk of RPL (42-46). Furthermore, Nelen 106 et al. demonstrated that the homozygosity for a common 677C→T mutation in the MTHFR gene leads 107 to a two-fold to three-fold higher risk of RPL (46). Another association study between MTHFR and RPL 108 was inconclusive, despite a large sample size of 1,830 cases and 3,037 controls (47). 109 110 Inflammation. Cytokines form a complex regulatory network which maintains homeostasis between the 111 foetus and maternal immune system. If this delicate balance is adversely affected, immunoregulatory 112 mechanisms may be insufficient to restore homeostasis and this may lead to pregnancy failure (48). 113
Variation especially at the inflammatory gene IL10 has been associated with REPL (OR=3.01, P-114 value<10 -4 ) (49) , whereas the evidence between its association with RPL has been less conclusive (50), 115 similarly to IL6 and RPL (51). In addition, the chemokine IL-8 is a crucial player in the process of 116 implantation, promoting trophoblastic cells migration and invasion (52). Moreover, microRNA studies 117 for endometriosis have shown the potential role of IL-8 levels in the pathogenesis of endometriosis via 118 stimulating endometrial stromal cell invasiveness (52). 119
120
Given the current knowledge about the genetic contribution to idiopathic RPL, we aimed to evaluate the 121 predictive ability of a combined gene set of RPL associated DNA variants to the risk of RPL in a 122
Ukrainian sample of 114 cases and 106 healthy controls. We genotyped variants at/within 12 genes 123 reflecting the main biological pathways involved in pregnancy maintenance: blood coagulation (F2, F5, 124 was determined in case of at least two consequent miscarriages in the first trimester (mean number of 134 foetal losses 2.7, SD 0.9). The American Society for Reproductive Medicine defines RPL as two or 135 more clinical pregnancy losses, not necessary consecutive, documented by ultrasonography or 136 histopathologic examination (53) . In order to ensure the idiopathic nature of RPL in the studied patients, Venous blood samples from patients and control group individuals were collected into 4ml vacutainer 152 tubes containing EDTA. Genomic DNA was extracted from blood samples by standard method using 153 proteinase K with the following chlorophorm extraction. We used 13 genetic variants previously 154 associated with RPL in European populations or those representing genetic networks of pathological 155 processes leading to RPL ( Table 1 provides information about variants and reference papers). A SNP 156 located in IL10 gene (rs1800872) was excluded from the polygenic risk score calculation due to high 157 LD (r 2 =0.26 in Europeans) with a nearby SNP included in the study (rs1800896). Genotyping for 158 selected polymorphic variants was performed by common variations of PCR-based assays as described 159 previously ( Table 1 ) with slight modifications. We identified genotypes for all genotyped individuals 160 without any missing values. However, genotyping of the 13 variants was done for the individuals 161 depending on their time of joining the project and availability of the reagents ( 
Association analysis 165
We performed single-variant association analyses between each of genotyped variants and RPL. We 166 used logistic regression for single-variant analyses assuming a log-additive model of association, 167 similarly to standard assumptions in GWAS. We report estimates of ORs along with their 95% 168 confidence intervals (CIs). 169 170 Genetic risk score calculation 171
We calculated the genetic risk score (GRS) using information from a set of 12 variants previously 172 associated with recurrent pregnancy loss (RPL) ( Table 1) . Among genotyped variants, there are ten 173
SNPs, rs1799752 at ACE gene is an insertion/deletion (indel), and another is a tandem repeat (VNTR) 174 in the intron 4 of ENOS gene. The risk allele count for each SNP was weighted by its established effect 175 size using previously published findings. The effect sizes were estimated from the odds ratios (ORs) in 176 the form of beta coefficients (log(OR)) for association between GRS and RPL assuming an additive 177 genetic model for association. The weighted GRS was corrected for missing genotypes by multiplying 178 the score with the total number of variants and then dividing by the number of genotyped variants per 179 person, i.e. the scores for people with less genotyped variants got more weight (54). The effect estimate 180 for rs1800896 located at IL10 was from a multi-ethnic study, discordant from our study's ethnic descent. 181
We therefore used the present study effect estimate, which was still smaller than that published for the 182 other IL10 variant. In addition, for the variants in F7, GP1A, ADRB2 and IL8 there were no published 183 studies for their association with RPL. Hence, we used the effect sizes from our data as weights. As a 184 sensitivity check we also calculated the GRS using weights from our study only. Finally, we calculated 185 an unweighted GRS and evaluated its effect on RPL. 186 187
Receiver operating characteristic analysis 188
Next, we performed receiver operating characteristic (ROC) analysis to determine the predictive value 189 of the estimated GRS in RPL. The efficacy of the GRS prediction is measured using the area under the 190 curve (AUC) which is the statistic calculated on the observed case scale. The statistical analyses were 191 conducted using the statistical software pROC package in R along with other functions (55) . 192
193
Results 194
Association analysis 195
We tested the 13 genetic variants for association with RPL in the REPLIK study from Ukraine. 
Receiver Operator Characteristic analysis 209
The ROC analysis showed an area under the curve (AUC) of 0.64 (95% CI [0.57, 0.72]). This indicates 210 a moderate to high ability for the GRS to correctly classify women with and without RPL. The sensitivity 211 of 72% at the best discriminating point implies that the GRS can effectively identify women having 212 experienced pregnancy losses (Figure 1) . The AUCs for the GRS using our study effect estimates as In this study we evaluated the combined effect of 12 genetic variants on RPL risk through GRS 218 implemented in a case-control REPLIK study from the Ukraine. We showed that even with such a small 219 number as 12 variants, when carefully chosen, we can already achieve predictive ability using weighted 220
GRSs. 221
with RPL (17,31,49), whereas others (within F7, GP1A, ESR1, ADRB2, ENOS, MTHFR, IL6, IL8) were 224 chosen for their hypothesised biological mechanisms (18, 19, 23, 27, 28, 47, 51, 52, 56) . The difficulty in 225 establishing genetic associations with the complex condition of RPL was reflected in our single-variant 226 analyses, i.e. we could not confirm the associations with RPL for majority of the variants with our 227 available sample. A likely contributing factor was the relatively small sample size for some of the 228 variants due to our genotyping strategy. For the IL10 variant, having the whole sample genotyped, we 229 demonstrated its association with RPL with a similar to previous study effect estimate (49) . 230
231
It has been acknowledged that the discrete genetic variants for RPL have a relatively low sensitivity and 232 specificity (3). Each individual case of idiopathic RPL usually cannot be explained by one risk factor 233 and should be treated as a multifactorial condition (9). Indeed, GWAS for complex traits have shown 234 that individual genetic variants usually provide relatively modest contribution to the trait variability in 235 terms of their per-allele effect size, typically in the per-allele effects being within the range of 5-10% 236 increase in risk in relation to that of risk estimated in general population (57), and hence require large 237 sample sizes for detection. Therefore, it may be more effective to evaluate the risk of RPL using a panel 238 of population-specific low-effect genetic markers, representing distinct physiological gene networks. 239
Our selection of the gene panel based on the hypothesised biological pathways proved successful since 240 by combining their effects, we could already predict the risk of RPL in our cohort. The results were not 241 influenced by the selection of the weights, as our sensitivity analyses showed. It is worth noticing that 242
we achieved an AUC of 0.64 (95% CI 0.57-0.72) with already 12 SNPs. A recent study combining 243 millions of SNPs into genome-wide polygenic scores for several complex diseases achieved AUCs of 244 similar strength. For example, an AUC of 0.63 was reported for inflammatory bowel disease from a 245 GRS consisting of 6.9 million SNPs (58). Taken together, our results are important considering that RPL 246 is a laborious and expensive phenotype to collect. Since the start of large-scale genome-wide association 247 studies, RPL has lacked novel insights establishing its underlying genetic mechanisms with no major 248 publications probably due to clinical requirements to the phenotype definition. However, our 249 investigation suggests that even a small number of SNPs in appropriately defined cases and controls can 250 be used for predictive purposes. 251
252
One important limitation of RPL genetic association studies arises from the fact that even though the 253 differences in population frequencies of studied genetic polymorphisms may be significant, ethnicity-254 specific associations are rarely addressed. Moreover, a vast majority of studies are performed on 255
European and American Caucasians, as well as, less frequently, Southern or Eastern Asians (5, 23, 59) . 256
On one hand, this situation allows increasing the significance of discovered effects in European 257 populations through meta-analyses (17). On the other hand, it complicates adoption of such effect 258 estimates for other ethnic groups due to possible difference in allele frequencies and effect size estimates 259 between populations and ethnic groups (23, 56) . 260
261
In summary, with the careful selection of the DNA variant set and the implementation of methods such 262 as the GRS, we can predict susceptibility to complex multifactorial conditions such as RPL. With the 263 hope of future well-powered studies, especially GWAS, adding to the knowledge of biological pathways 264 not hypothesised previously for RPL, we will able to further improve the prediction and identification 265 for the GRS and with estimates for specificity and sensitivity at that point. Abbreviation: AUC, area 5 under the curve. 6 7 8
